menu

CME: Role of JAK-STAT Pathway in Rheumatoid Arthritis Disease Progression

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Role of JAK-STAT Pathway in Rheumatoid Arthritis Disease Progression

Role of JAK-STAT Pathway in Rheumatoid Arthritis Disease Progression
RestartResume
A better understanding of RA immunopathogenesis has lead to a targeted approach to therapy. Learn more about the role of the JAK-STAT pathway!

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    An ongoing mission in rheumatology is to better understand the complex mechanisms behind the inflammatory process responsible for the joint destruction in rheumatoid arthritis, or RA, to guide new treatment approaches. One such mediator called the JAK-STAT pathway has become an important therapeutic target because of its known role in RA disease progression.

    Dr. Matt Birnholz is joined by Dr. Alan Epstein, Clinical Professor of Medicine at the University of Pennsylvania School of Medicine, to discuss the JAK-STAT pathway in more detail.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Matt Birnholz, MD
    Medical Director
    ReachMD
    Chicago, IL

    Matt Birnholz, MD has nothing to disclose.  

    Faculty:
    Alan Epstein, MD
    Clinical Professor of Medicine
    University of Pennsylvania
    School of Medicine
    Philadelphia, PA

    Alan Epstein, MD has disclosed Commercial Interest Speakers Bureau from AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, Quest, and Sanofi-Regeneron. 

    Reviewers/Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Samantha Lare has nothing to disclose. 
    • Richard S. Pope, MPAS, PA-C has nothing to disclose.  
    • Ashley Pluta has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with RA.  After participating in this educational activity, participants should be better able to: 

    • Explain the role of JAK/STAT activation in RA disease progression
    • Identify available and emerging agents capable of inhibiting the JAK/STAT intracellular pathway and cytokine production
  • Target Audience

    This activity is designed to meet the educational needs of rheumatologists, nurses, nurse practitioners, physician assistants and pharmacists who are involved in the management of patient with rheumatoid arthritis.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and National Institute on Drug Abuse (NIDA). TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    No commercial support has been provided for this activity.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.